High index of suspicion required for SS

Article

A high index of suspicion is required for underlying Sjögren's syndrome (SS) in patients with clinically significant aqueous-deficient dry eye.

A high index of suspicion is required for underlying Sjögren's syndrome (SS) in patients with clinically significant aqueous-deficient dry eye.

The industry-sponsored multicentre clinical trial, led by Dr Esen K Akpek, Department of Cornea and External Disease Service, Ocular Surface Diseases and Dry Eye Clinic, The Wilmer Eye Institute, Baltimore, Maryland, USA, involved 327 patients with clinically significant aqueous-deficient dry eye.

Schirmer test, corneal fluorescein staining, conjunctival lissamine green staining, and tear-film breakup time were the ocular tests used to assess all patients. The team obtained review of systems questionnaire, medical history, dry eye questionnaire and laboratory work-up (Sjögren-specific antibody A (SSA), Sjögren-specific antibody B (SSB), rheumatoid factor (RF) and antinuclear antibody (ANA).

Of the patients studied, 38 had SS with 28 primary SS (pSS), and 17 with secondary SS. It was discovered that SS patients had significantly worse conjunctival and corneal staining, Schirmer test and symptoms compared with patients without SS. Primary SS was more likely to occur in patients with positive ANA and RF.

The abstract can be found in the British Journal of Ophthalmology.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.